Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study
Fraz A Ismat, Helen H Usansky, Raul Villa, Jun Zou, Ariel Teper, Fraz A Ismat, Helen H Usansky, Raul Villa, Jun Zou, Ariel Teper
Abstract
Introduction: Treprostinil is a prostacyclin vasodilator widely used for the treatment of pulmonary arterial hypertension (PAH) and, in its inhaled form, for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Treprostinil palmitil inhalation powder (TPIP) is a dry powder formulation of treprostinil palmitil (TP), an ester prodrug of treprostinil. TPIP is designed to provide sustained release of treprostinil in the lung over a prolonged period, potentially enabling a once-daily (QD) dosing regimen and significantly higher tolerated doses compared with currently available treprostinil formulations. This phase 1 study assessed the safety, tolerability, and pharmacokinetics of TP and treprostinil following single and multiple QD administrations of TPIP in healthy volunteers.
Methods: Healthy adults (aged 18-45 years) were randomized to receive single or multiple QD inhalation doses of TPIP. Participants in the single-dose phase received TPIP 112.5, 225, 450, or 675 µg (n = 6/dose) or placebo (n = 2). Participants in the multiple-dose phase received TPIP 225 µg QD for 7 days (n = 6), 112.5 µg QD for 4 days followed by 225 µg QD for 3 days (n = 6), or placebo for 7 days (n = 4).
Results: Overall, 41 of 42 participants (97.6%) completed the study. In the single-dose phase, 70.8% (n = 17/24) of TPIP-treated participants experienced a treatment-emergent adverse event (TEAE) vs 0% (n = 0/2) of placebo-treated participants; the most common TEAEs (≥ 20%) were cough (45.8%), dizziness (29.2%), and throat irritation (20.8%). In the multiple-dose phase, 83.3% (n = 10/12) of TPIP-treated participants experienced a TEAE vs 50.0% of placebo-treated participants (n = 2/4); the most common TEAEs were cough (58.3% TPIP vs 50.0% placebo), headache (50.0% vs 0%), nausea (33.3% vs 0%), chest discomfort (33.3% vs 0%), and dizziness (25.0% vs 0%). Most TEAEs were mild; only seven patients experienced a moderate TEAE, and no severe or serious TEAEs occurred. In the multiple-dose phase, participants whose doses were titrated from TPIP 112.5 µg QD to 225 µg QD experienced fewer TEAEs than those who received 225 µg QD at treatment initiation (66.7% vs 100.0%), and all TEAEs with dose titration were mild. After a single dose of TPIP, treprostinil elimination t1/2 was 8.67-11.6 h and exposure was dose proportional, with mean (CV%) Cmax 78.4-717 pg/mL (38.6-72.9%) and AUC0-∞ 1090-5480 pg·h/mL (11.5-30.0%). At steady state (TPIP 225 µg), the mean (CV%) of Cmax, Cmin, and AUCτ were 193-228 pg/mL (32.9-46.4%), 17.6-22.8 ng/mL (43.7-64.4%), and 1680-1820 pg·h/mL (28.7-36.6%), respectively. The elimination t1/2 was 6.84-8.82 h after repeat dosing. No steady-state accumulation was observed. Plasma concentrations of TP were below the limit of quantification (100 pg/mL) at all time points measured.
Conclusion: TPIP was well tolerated at the doses tested, and dose titration improved tolerability. Treprostinil pharmacokinetics were linear and supportive of a QD treatment regimen. These results support further development of TPIP in patients with PAH and PH-ILD.
Keywords: Interstitial lung disease; Pharmacokinetics; Phase 1 study; Pulmonary arterial hypertension; Pulmonary hypertension; Treprostinil; Treprostinil palmitil inhalation powder.
© 2022. The Author(s).
Figures
References
- Leifer FG, Konicek DM, Chen KJ, et al. Inhaled treprostinil-prodrug lipid nanoparticle formulations provide long-acting pulmonary vasodilation. Drug Res (Stuttg) 2018;68:605–614. doi: 10.1055/s-0044-100374.
- Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ. 2021;11:2045894020977300. doi: 10.1177/2045894020977300.
- Coons JC, Pogue K, Kolodziej AR, Hirsch GA, George MP. Pulmonary arterial hypertension: a pharmacotherapeutic update. Curr Cardiol Rep. 2019;21:141. doi: 10.1007/s11886-019-1235-4.
- Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913. doi: 10.1183/13993003.01913-2018.
- Parikh V, Bhardwaj A, Nair A. Pharmacotherapy for pulmonary arterial hypertension. J Thorac Dis 2019;11:S1767–81. 10.21037/jtd.2019.09.14.
- Corboz MR, Salvail W, Gagnon S, et al. Prostanoid receptor subtypes involved in treprostinil-mediated vasodilation of rat pulmonary arteries and in treprostinil-mediated inhibition of collagen gene expression of human lung fibroblasts. Prostaglandins Other Lipid Mediat. 2021;152:106486. doi: 10.1016/j.prostaglandins.2020.106486.
- Whittle BJ, Silverstein AM, Mottola DM, Clapp LH. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012;84:68–75. doi: 10.1016/j.bcp.2012.03.012.
- Lambers C, Kornauth C, Oberndorfer F, et al. Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells. PLoS ONE. 2018;13:e0205195. doi: 10.1371/journal.pone.0205195.
- LeVarge BL, Channick RN. Inhaled treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Respir Med. 2012;6:255–265. doi: 10.1586/ers.12.23.
- Chapman RW, Corboz MR, Malinin VS, et al. An overview of the biology of a long-acting inhaled treprostinil prodrug. Pulm Pharmacol Ther. 2020;65:102002. doi: 10.1016/j.pupt.2021.102002.
- LeVarge BL. Prostanoid therapies in the management of pulmonary arterial hypertension. Ther Clin Risk Manag. 2015;11:535–547. doi: 10.2147/TCRM.S75122.
- Channick RN, Voswinckel R, Rubin LJ. Inhaled treprostinil: a therapeutic review. Drug Des Devel Ther. 2012;6:19–28. doi: 10.2147/DDDT.S19281.
- Chapman RW, Corboz MR, Fernandez C, et al. Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil. ERJ Open Res. 2021;7:00592–2020. doi: 10.1183/23120541.00592-2020.
- Tyvaso [package insert]. Research Triangle Park, NC: United Therapeutics Corp., 2021.
- Chapman RW, Li Z, Corboz MR, et al. Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil. Pulm Pharmacol Ther. 2018;49:104–111. doi: 10.1016/j.pupt.2018.02.002.
- Corboz MR, Li Z, Malinin V, et al. Preclinical pharmacology and pharmacokinetics of inhaled hexadecyl-treprostinil (C16TR), a pulmonary vasodilator prodrug. J Pharmacol Exp Ther. 2017;363:348–357. doi: 10.1124/jpet.117.242099.
- Chapman RW, Corboz MR, Fernandez C, et al. Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil [supplemental appendix]. ERJ Open Res. 2021;7:00592–2020. . Accessed Mar 17 2022.
- Han D, Fernandez C, Sullivan E, et al. Single dose pharmacokinetics of C16TR for Inhalation (INS1009) vs treprostinil inhalation solution [PA2398]. Eur J Respir. 2016;48(suppl 60). Abstract PA2398. 10.1183/13993003.congress-2016.PA2398.
- Han D, Fernandez C, Sullivan E, et al. Safety and pharmacokinetics study of a single ascending dose of C16TR for inhalation (INS1009). Eur J Respir. 2016;48(suppl 60). Abstract PA2403. 10.1183/13993003.congress-2016.PA2403.
Source: PubMed